-+ 0.00%
-+ 0.00%
-+ 0.00%

Impact Therapeutics says ESMO 2026 accepts posters on senaparib, IMP1734 and IMP1707 data

PUBT·07/19/2026 23:30:48
Listen to the news
Impact Therapeutics says ESMO 2026 accepts posters on senaparib, IMP1734 and IMP1707 data
  • Impact Therapeutics disclosed multiple oncology study abstracts accepted for poster presentation at the 2026 ESMO Congress in Madrid, Oct. 23-27.
  • Key update includes refreshed Phase 3 FLAMES progression-free survival data for senaparib in first-line maintenance advanced ovarian cancer.
  • Posters also feature updated Phase I/II data for PARP1-selective IMP1734 in combinations for solid tumors, metastatic prostate cancer.
  • Initial first-in-human Phase I/II results for CNS-penetrant PARP1 inhibitor IMP1707 in HRR-mutated advanced solid tumors to be presented.
  • Senaparib’s European marketing authorization application was accepted by the EMA in August 2025; approval expected in 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260720-12249032), on July 19, 2026, and is solely responsible for the information contained therein.